2017 Fiscal Year Final Research Report
Development of new treatments with suppression of RAGE signal for pulmonary hypertension
| Project/Area Number |
15K09158
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Cardiovascular medicine
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
赤木 達 岡山大学, 医歯薬学総合研究科, 助教 (60601127)
阪口 政清 岡山大学, 医歯薬学総合研究科, 准教授 (70379840)
伊藤 浩 岡山大学, 医歯薬学総合研究科, 教授 (90446047)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Keywords | 肺高血圧症 / ナノメディシン / 終末糖化産物受容体 / 肺動脈平滑筋細胞 / drug delivery system / 細胞増殖 / 右室収縮期圧 / 右室肥大 |
|---|
| Outline of Final Research Achievements |
1.After a single administration, imatinib or beraprost-nanoparticles significantly decreased right ventricular pressure and right ventricular hypertrophy in rat models of pulmonary arterial hypertension (PAH).
2.Pulmonary artery smooth muscle cells of PAH (PAH-PASMCs) were hyperplastic. AS-1, an inhibitor of TIR domain-mediated RAGE signaling, significantly inhibited overgrowth in PAH-PASMCs.
|
| Free Research Field |
循環器内科学・分子細胞生物学・肺高血圧症
|
